公开(公告)号：US20230115867A1

公开(公告)日：2023-04-13

申请号：US18072752

申请日：2022-12-01

申请人： Kowa Company, Ltd.

发明人： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC分类号： A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K38/13 ,  A61P3/06 ,  A61K31/7048

摘要： To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US20220296588A1

公开(公告)日：2022-09-22

申请号：US17708706

申请日：2022-03-30

申请人： Kowa Company, Ltd.

发明人： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC分类号： A61K31/496 ,  A61K38/13

摘要： To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US20220257627A1

公开(公告)日：2022-08-18

申请号：US17708740

申请日：2022-03-30

申请人： Kowa Company, Ltd.

发明人： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC分类号： A61K31/7048 ,  A61K31/423 ,  A61P3/06

摘要： To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US20240277745A1

公开(公告)日：2024-08-22

申请号：US18564115

申请日：2022-05-25

申请人： KOWA COMPANY, LTD

发明人： Noboru KANETA ,  Ryu OSHIMA ,  Shona Sanchita PENDSE ,  Ryohei TANIGAWA

IPC分类号： A61K31/7048 ,  A61K31/423 ,  A61P1/16

CPC分类号： A61K31/7048 ,  A61K31/423 ,  A61P1/16

摘要： Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.

公开(公告)号：US20240207233A1

公开(公告)日：2024-06-27

申请号：US18401556

申请日：2023-12-31

申请人： KOWA COMPANY, LTD.

发明人： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC分类号： A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K31/7048 ,  A61K38/13 ,  A61K45/06 ,  A61P3/06

CPC分类号： A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K31/7048 ,  A61K38/13 ,  A61P3/06 ,  A61K45/06

摘要： To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.